Literature DB >> 21166338

Cloninger's temperament and character dimension of personality in patients with asthma.

Medine Yazici Gulec1, Huseyin Gulec, Funda Oztuna, Samet Kose.   

Abstract

OBJECTIVE: Psychosocial factors have been implicated as being important in the onset and/or exacerbation of asthma. This study was performed to evaluate the personality profiles of asthma patients.
METHOD: Ninety-five asthmatic, 98 psoriatic patients, and 96 healthy controls completed the Temperament and Character Inventory (TCI), Beck Anxiety Inventory (BAI), and Beck Depression Inventory (BDI). The relationships between asthma illness duration, asthma severity score, depression, anxiety, and temperament and character personality variables were evaluated.
RESULTS: Asthmatic patients had significantly higher mean scores on the BAI, Harm Avoidance, Persistence, and Self-transcendence dimensions and lower scores on the BDI, Novelty Seeking, and Reward Dependence dimensions of the TCI than the psoriatic patients. Significant group effect was found for the BDI and BAI scores in between groups. Significant differences in TCI scores were found across groups except for Persistence and Self-transcendence. Post hoc tests revealed significantly lower Novelty Seeking, higher Harm Avoidance, lower Reward Dependence, and higher Self-transcendence scores in patients with asthma. Regression analysis revealed a significant effect between duration of illness and Persistence and Self-transcendence. Illness severity had a significant effect on the Harm Avoidance. Anxiety scores had significant effect on the Harm Avoidance, Self-directedness, and Self-transcendence. Depression scores had no significant effect on any of the TCI dimensions.
CONCLUSIONS: Asthmatic patients can be distinguished by a specific pattern of temperament (low NS) and character (high ST) dimensions and compared with both psoriatic patients and healthy controls. Illness duration is associated with ST scores, and illness severity is associated with HA.

Entities:  

Mesh:

Year:  2010        PMID: 21166338     DOI: 10.2190/PM.40.3.d

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  7 in total

1.  Temperament and character profiles of male COPD patients.

Authors:  Hasan Kahraman; Fatma Ozlem Orhan; Mustafa Haki Sucakli; Ali Ozer; Nurhan Koksal; Bilal Sen
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Bronchial asthma control degree and the temperament structure according to the Eysenck model.

Authors:  Andrzej Witusik; Lukasz Mokros; Piotr Kuna; Tadeusz Pietras
Journal:  Postepy Dermatol Alergol       Date:  2019-03-04       Impact factor: 1.837

3.  Divergent immune responses in behaviorally-inhibited vs. non-inhibited male rats.

Authors:  Kerry C Michael; Robert H Bonneau; Rebecca A Bourne; LaDara Godbolt; Michael J Caruso; Christine Hohmann; Sonia A Cavigelli
Journal:  Physiol Behav       Date:  2019-10-17

4.  Temperament and stress coping styles in bronchial asthma patients.

Authors:  Michał Panek; Piotr Kuna; Andrzej Witusik; Radosław Wujcik; Adam Antczak; Tadeusz Pietras
Journal:  Postepy Dermatol Alergol       Date:  2016-12-02       Impact factor: 1.837

5.  The role of anxious temperament in patients with allergic rhinitis.

Authors:  Halil Ibrahim Tas; Ozge Caglar
Journal:  Saudi Med J       Date:  2019-01       Impact factor: 1.484

6.  Transcriptomic and Network Analyses Reveal Immune Modulation by Endocannabinoids in Approach/Avoidance Traits.

Authors:  Andrea Termine; Carlo Fabrizio; Juliette Gimenez; Anna Panuccio; Francesca Balsamo; Noemi Passarello; Silvia Caioli; Luana Saba; Marco De Bardi; Francesco Della Valle; Valerio Orlando; Laura Petrosini; Daniela Laricchiuta
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

7.  Temperament and character properties of primary focal hyperhidrosis patients.

Authors:  Mehmet Ak; Didem Dincer; Bikem Haciomeroglu; Suleyman Akarsu; Alper Cinar; Nergis Lapsekili
Journal:  Health Qual Life Outcomes       Date:  2013-01-11       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.